Investigating the role of the ISR pathway in dopamine neurons related to Parkinson's disease
The ISR pathway in Dopamine Neurons: Perpetrator or Protector in Parkinson's Disease
This study is looking at how a specific stress response in the brain affects the nerve cells that produce dopamine in people with Parkinson's disease, hoping to find new ways to help keep these cells healthy and develop better treatments for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11007180 on NIH RePORTER |
What this research studies
This research explores how the integrated stress response (ISR) pathway affects dopamine neurons in Parkinson's disease. It aims to understand the balance between cell survival and death in these neurons, particularly how excessive activation of the ISR may contribute to the degeneration seen in Parkinson's. By studying both human samples and mouse models, the research seeks to uncover the underlying mechanisms that lead to neuronal death and potentially identify new therapeutic targets. Patients may benefit from insights that could lead to novel treatments for this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease, particularly those in advanced stages of the condition.
Not a fit: Patients with early-stage Parkinson's disease or those with other movement disorders unrelated to dopamine neuron degeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that modify the progression of Parkinson's disease.
How similar studies have performed: Previous research has shown that targeting stress response pathways can be beneficial in neurodegenerative diseases, suggesting potential for success in this approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Lockshin, Elana — Duke University
- Study coordinator: Lockshin, Elana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.